Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 27, Status: Authorised

The updated EPAR for Iclusig (ponatinib) signifies a significant R&D advance in the field of oncology. Highlighting efficacy against CML and Ph+ ALL, including the T315I mutation, with dose optimization, this update provides valuable insights for drug developers, clinicians, and researchers working on targeted therapies for leukemia, especially in cases of resistance or intolerance to other TKIs.